NBME Free 120 Tumor necrosis factor α (NBME Answers)

need help with your account or subscription? click here to email us (or see the contact page)

search for anything ⋅ score predictor (“predict me!”)

NBME Free 120 Answers

free120/Block 3/Question#15 (reveal difficulty score)
A 46-year-old woman with active ankylosing ...
Tumor necrosis factor α 🔍 / 📺 / 🌳 / 📖
tags: pharm Immuno

+6 upvote downvote
submitted by ∗em_goldman(30)

Rituximab (anti-CD 20) is currently undergoing trials for AS. My sparse googling just now shows that rituximab probably only has a moderate effect, so probably second-line to anti-TNFa therapy. Probably.

Safe to say for boards that AS: TNFa > CD20

cheesetouch FA 2018 - rituximab p 430 -- - use for Nonhodgkins lymphoma, CLL, ITP, Rheumatoid arthritis TNF-a inhibitors - p 472: 1) etanercept for Ra, psoriasis, ankylosing spondylitis. 2) infliximab and other mAB for IBD, RA, AS, psoriasis +3

+2 upvote downvote
submitted by ∗osler_weber_rendu(160)

Monoclonal Antibodies are always last resort! I just use this as a general rule

+1 upvote downvote
submitted by ∗bwdc(697)

Many autoimmune/autoinflammatory conditions, including ankylosing spondylitis, are treated with DMARDs like anti-TNF-alpha medications when milder stuff doesn’t do the trick. Common examples are infliximab (Remicade) and adalimumab (Humira).

Must-See Comments from free120

sugaplum on It is a polymorphism
bwdc on Elaboration of proteases and urease with ...
bwdc on Hypercoagulability from advanced malignancy
bwdc on Ribosomal assembly
bwdc on Aspiration
bwdc on Amygdala
imnotarobotbut on von Willebrand disease
bwdc on Trinucleotide repeat expansion
bwdc on Mediation of cell entry via a fusion protein
bwdc on Metabolism
bwdc on Basement membrane
melchior on Aspiration
hungrybox on Immune complex deposition in tissues
aejinkim on Decreased activity in the enzyme that ...